Identifying the causes of type 1 diabetes and autoimmunity

John Todd
John Todd

Scientific title: JDRF/Wellcome Diabetes and Inflammation Laboratory
Principal Investigator:
 Professor John Todd
Institution: University of Oxford
Project duration: 01/10/2015 – 30/09/2020

Objective: This partnership with Wellcome funds the work of Professor John Todd and his team, the “DIL”, They have identified a number of genes that seem to increase a person’s risk of developing type 1, and have traced out what effect those genes have on the body that might be behind this influence on type 1.

Once they know what these genes do, Todd’s team may be able to counteract them, and therefore reduce a person’s chances of developing type 1.

The team’s work has already led to a clinical trial, called DILT1D. Both studies of the interleukin-2 drug, aldesleukin, have now completed recruitment. The results for DILT1D published here.

You can read more about the JDRF/Wellcome Diabetes and Inflammation Laboratory, which has now moved to Oxford, on their website. Their third clinical project will be a trial in children with type 1 diabetes to test if ultra low-dose aldesleukin can preserve insulin secretion.

 

Categories: Cure, Prevent, Partnership, Immune Therapies